UROTHELIAL CANCER

This study is for people with metastatic urothelial cancer, a type of bladder cancer that has spread. It tests two antibody-drug conjugates (sacituzumab govitecan and enfortumab vedotin) with or without the immunotherapy pembrolizumab. The goal is to find the safest doses and see…

This study tests a new drug called AVZO-103 in people with advanced bladder cancer or other solid tumors that have spread. The drug is designed to attack cancer cells directly. The main goals are to find a safe dose and see if it shrinks tumors. About 355 adults will take part.

This early-phase study tests a new drug called SLV-154 in about 70 people whose solid tumors (like head and neck, lung, breast, or ovarian cancer) have spread. The main goal is to find a safe dose and watch for side effects. Participants must have a confirmed diagnosis and be in …

This early-stage study tests a new drug called STRO-004 in about 200 adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in m…

This study tests a two-drug treatment (gemcitabine and Jelmyto) for a type of high-risk urinary tract cancer. The goal is to destroy the tumor while keeping the kidney intact, avoiding the standard surgery that removes the kidney. About 28 adults with non-invasive, high-grade can…

This study tests a new drug, datopotamab deruxtecan (Dato-DXd), combined with standard chemotherapy (carboplatin or cisplatin) in people with advanced bladder cancer that worsened after prior treatment with enfortumab vedotin and pembrolizumab. About 630 adults will be randomly a…

This study is for people with advanced solid tumors like melanoma, lung cancer, or liver cancer. It tests whether adding metformin or rosiglitazone (drugs that change how cells use energy) to standard immunotherapy (anti-PD-1) can improve treatment response. Participants will hav…

This study tests whether a combination of two drugs (enfortumab vedotin and pembrolizumab) can control muscle-invasive bladder cancer and allow patients to keep their bladder. About 390 adults whose cancer hasn't spread outside the bladder and who cannot or choose not to have bla…

This study tests a new medicine, PF-08634404, for adults with advanced bladder cancer that has spread. Some participants get the drug alone, others get it with another cancer drug. The goal is to see if the treatment is safe and shrinks tumors. About 132 people will take part.

This study tests a new drug called datopotamab deruxtecan (Dato-DXd) alone or with other cancer drugs in people with advanced solid tumors that have spread. The goal is to see if the drug can shrink tumors or slow cancer growth. About 454 adults with cancers like endometrial, gas…

This study tests a new drug called izalontamab brengitecan against standard chemotherapy for people with advanced bladder cancer that got worse after immunotherapy. About 470 adults will be randomly assigned to receive either the new drug or chemo. The goal is to see if the new d…

This early-phase study tests two drugs, bintrafusp alfa and PDS01ADC, alone or with targeted radiation, in adults with metastatic bladder, kidney, or other non-prostate genitourinary cancers. The goal is to see if the combination helps the immune system fight cancer better. About…

This study looks at whether checking DNA and proteins in urine can find bladder and kidney cancers without needing a scope or surgery. Researchers will collect urine samples from 500 adults, including those with known or suspected cancer and healthy volunteers. The goal is to see…

This early-phase study tests a new imaging drug called [18F]DK222 in 6 people with lung or bladder cancer. The drug is designed to attach to PD-L1, a protein that helps cancer hide from the immune system. Researchers want to see if the drug is safe, how it moves through the body,…

This study looks at nerve damage (peripheral neuropathy) in people with advanced bladder cancer who are getting a new two-drug treatment. About 80 patients will be followed for a year to see how often nerve problems occur and how they affect daily life. The goal is to better unde…

This study watches adults in South Korea with advanced bladder cancer who are already prescribed PADCEV. It does not give any new treatment—only collects information from medical records for up to a year. The goal is to track side effects and how well the drug works in everyday u…

This study follows 1,100 adults with common and rare urinary tract cancers (like bladder, kidney, or testicular cancer) over their lifetime. Researchers collect medical records, blood, urine, and tumor samples to understand how these cancers behave and respond to treatments. The …

This study collects blood, urine, saliva, and tumor tissue from people with or at risk for urothelial cancer, as well as from healthy volunteers. The goal is to analyze DNA and other molecular changes to learn what causes this cancer and how it responds to treatment. Participants…